ClinicalTrials.gg
RecruitingNCT06066268miRNACLIUpdated Nov 5, 2026

miRNAs in Critical Limb Ischemia (miRNACLI)

An observational study in Critical Limb Ischemia, sponsored by IRCCS Policlinico S. Donato. Recruiting at 1 site in Italy. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by IRCCS Policlinico S. Donato · Observational

How we know

From the registry’s dates

  • Started May 2016; still recruiting 10 years 5 months later.
Updated Nov 5, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
80
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Chronic Limb-Threatening Ischemia with a site in Italy — 5 open to participants now, 5 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · Italy.

Planned enrollment
10th of 10
80 · median 161
Started
2016
with 1 other
Observational
10 of 24
3 open now
Registered
22nd of 24
by date

Among the 24 studies in Chronic Limb-Threatening Ischemia with a site in Italy, this one is the 10th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2016, is one of 10 observational ones, and was the 22nd registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

5 of the 24 studies in Chronic Limb-Threatening Ischemia with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Chronic Limb-Threatening Ischemia with a site in Italy, or all of them as a file.
02

Study summary

For the present study, 40 patients affected by critical limb ischemia of different severity will be enrolled: patients affected by critical limb ischemia undergoing subgenual femoropopliteal bypass; patients suffering from terminal ischemia causing gangrene and therefore undergoing major amputation of the lower limb. Biopsies from the first 20 enrolled patients will be used for miRNA profiling. The total of 40 biopsies obtained from all enrolled patients will instead be used for the validation of the miRNAs identified in the profiling.

The results obtained will be compared with those obtained in 40 control patients affected by infrarenal abdominal aortic aneurysm (AAA) undergoing endovascular exclusion surgery (EVAR) of the AAA without any ischemia of the lower limbs. Also in this case the biopsies of the first 20 control patients enrolled will be used for miRNA profiling. The total of 40 biopsies obtained from all control patients will instead be used for the validation of the miRNAs identified in the profiling. A total of 80 patients (40 cases and 40 controls) will be enrolled.

Read the detailed description

The analyzes of the expression of miRNAs and the RISC complex will be carried out on fragments of skeletal muscle taken from different sites depending on whether they are cases or controls.

Cases:

  • Patients suffering from CLI undergoing lower limb revascularization via subgenual femoropopliteal bypass: Gastrocnemius muscle biopsies will be taken.
  • Patients suffering from terminal CLI and/or gangrene of the lower limb undergoing thigh amputation: biopsies will be taken in different muscle districts. In particular, biopsies of the Sartorius or Vastus lateralis muscle will be taken at the amputation site, both from the proximal muscle belly which remains covering the bone stump, and from the part of the muscle belly sacrificed with the amputated limb. Biopsies of the Gastrocnemius and Tibialis anterior muscles will be taken from the amputated leg.
  • Patients suffering from terminal CLI and/or gangrene of the lower limb undergoing leg amputation: biopsies will be taken in different muscle districts. In particular, biopsies of the Gastrocnemius and Tibialis anterior muscles will be carried out at the amputation site, both from the proximal muscle belly which remains covering the bone stump, and from the part of the muscle belly sacrificed with the amputated limb.

Controls:

  • The control subjects will be represented by individuals affected by infrarenal abdominal aortic aneurysm (AAA) free from CLI, affected and not affected by type 2 diabetes mellitus, undergoing endovascular exclusion surgery of the AAA (EVAR), similar by age and sex to CLI patients. Sartorius muscle biopsies will be taken.

The analyzes of the expression of circulating miRNAs will be carried out on 2 7 ml tubes of peripheral venous blood, taken before the surgical incision from the same cases and controls described in the previous point.

03

Conditions studied

  • Critical Limb Ischemia

Keywords

  • microRNA
  • Ischemia
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Critical limb ischemia patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cases:

  • patients affected by CLI candidates for popliteal exploration surgery and/or subgenual femoropopliteal bypass.
  • Patients affected by CLI with irreversible ischemia and/or distal gangrene of the lower limb candidates for major amputation of the lower limb.

Controls:

  • patients affected by infrarenal abdominal aortic aneurysm (AAA) undergoing endovascular exclusion surgery of the AAA (EVAR) who are free from CLI, affected and not affected by type 2 diabetes mellitus.

Exclusion criteria

Exclusion Criteria:

  • Pregnant women
  • Patients carriers of genetic diseases
  • Patients suffering from malignant neoplasia
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
80 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • 1) Critical limb ischemia (CLI);

    1)Critical limb ischemia (CLI): * Patients suffering from CLI undergoing lower limb revascularization via subgenual femoropopliteal bypass. muscle biopsies willbe taken. * Patients suffering from terminal CLI and/or gangrene of the lower limb undergoing thigh amputation. Muscle biopsies will be taken. * Patients suffering from terminal CLI and/or gangrene of the lower limb undergoing leg amputation. Muscle biopsies will be taken.

    Diagnostic Test: Critical limb ischemia: analysis of RNAs

  • 2)Controls

    2)Controls: patients affected by infrarenal abdominal aortic aneurysm (AAA) free from CLI, affected and not affected by type 2 diabetes mellitus, undergoing endovascular exclusion surgery of the AAA (EVAR), similar by age and sex to CLI patients. Sartorius muscle biopsies will be taken.

    Diagnostic Test: Controls: analysis of RNAs

Interventions

  • Diagnostic testCritical limb ischemia: analysis of RNAs

    analysis of miRNA expression levels

  • Diagnostic testControls: analysis of RNAs

    analysis of miRNAs expression levels

06

What researchers measure

Primary outcomes

  1. Identification of potentially pathogenic miRNAs in CLI and related target mRNAs.

    Identify miRNAs and their targets that directly interact with the RNA Induced Silencing Complex (RISC) in muscle biopsies obtained from CLI patients.

    Time frame: 1 year to 10 years

  2. Identification of disease biomarkers

    Identify plasma miRNAs to be used as disease biomarkers that can be used to assess disease status and severity with a minimally invasive procedure.

    Time frame: 1 year to 10 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2016 (actual). Primary completion is estimated for Jan 2027, 128 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion May 2026 → Jan 2027 and completion May 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2023
First posted
Oct 4, 2023
StartActual
May 31, 2016
Primary completionEst.
Jan 31, 2027was May 2026
CompletionEst.
Jan 31, 2027was May 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 31, 2026→Jan 31, 2027
Nov 5, 2026
Study completion
May 31, 2026→Jan 31, 2027
Nov 5, 2026
Eligibility
Revised
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion May 31, 2026→Jan 31, 2027
    Study completion May 31, 2026→Jan 31, 2027
    Eligibility Revised
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06066268
Responsible party
Fabio Martelli (Dr., IRCCS Policlinico S. Donato) — Principal investigator
First posted
Oct 4, 2023
Start date
May 31, 2016
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Fabio Dr Martelli
Contact
fabio.martelli@grupposandonato.it
+39 0226437762
Giovanni Dr Nano, MD
Contact
giovanni.nano@grupposandonato.it
+39 0252771
Fabio Martelli
principal investigator · IRCCS Policlinico S. Donato

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion